Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-156-8 | CAS number: 25640-78-2
Acute Toxicity: other routes
Administrative data
- Endpoint:
- acute toxicity: other routes
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Documentation insufficient for assessment, only meeting abstract available; study subject does not correspond to REACH information requirements
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 975
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- After intraperitoneal application of single or multiple doses of gamma-methyl-4-phenylmandelic acid, a major metabolite of 4-isopropylbiphenyl, development of renal lesions was investigated. Renal lesions were also observed after application of 4-isopropylbiphenyl.
- GLP compliance:
- no
- Remarks:
- pharmacological programme
Test material
- Reference substance name:
- 4-isopropylbiphenyl
- EC Number:
- 230-420-1
- EC Name:
- 4-isopropylbiphenyl
- Cas Number:
- 7116-95-2
- Molecular formula:
- C15H16
- IUPAC Name:
- 4-Isopropylbiphenyl
- Details on test material:
- - Name of test material (as cited in study report): 4-isopropylbiphenyl major metabolite, gamma-4-phenylmandelic acid
- no further information
Constituent 1
Test animals
- Species:
- other: rats and dogs
- Strain:
- not specified
- Sex:
- not specified
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- not specified
- Doses:
- single of multiple doses of 250 mg/kg bw
- No. of animals per sex per dose:
- no data
Results and discussion
Effect levels
- Remarks on result:
- other: Increase in relative kidney weights; progressive alterations in function and structure of the kidney; time sequential changes of cortical tubules (4-8 h), collecting tubules (8-24 h) and papilla (24-48h)
- Mortality:
- no data
- Clinical signs:
- Increase in urine volume, serum creatinine, blood urea nitrogen, urine glutamic-oxalacetic transaminase, relative kidney weights, and decrease in urine specific gravity
- Gross pathology:
- Progressive alterations in function and structure of the kidney: papillary edema, dillated collecting tubules, degeneration and necrosis; dillated tubules contained precipitated proteins and minerals
- Other findings:
- - Histopathology: time sequential changes of cortical tubules (4-8 h), collecting tubules (8-24 h) and papilla (24-48h)
- Potential target organs: kidney
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
